Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
Xconomy
SEPTEMBER 18, 2020
Some of those analysts think Gilead might have overpaid but the company says there were competing offers. The $21 billion Immunomedics acquisition brings to Gilead a cancer drug that many analysts project will become a blockbuster seller. The drug, sacitizumab govitecan (Trodelvy), is what’s called an antibody drug conjugate (ADC).
67 
Let's personalize your content